ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 13, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a genome editing company focused on creating transformative medicine for serious diseases, today announced the receipt of the Kyle Bryant Translational Research Award from Friedreich’s Ataxia Research Alliance (FARA), a non-profit organization that is focused on curing Friedreich’s Ataxia (FA). The grant is awarded to fund research on in vivo CRISPR/Cas9-based gene-editing approaches to treat FA, which will be performed in collaboration with Dr. Marek Napierala at University of Alabama at Birmingham. This announcement coincides with FARA’s rideATAXIA Philadelphia event, a lead location in an annual bike ride program founded by patient Kyle Bryant, that increases FA awareness and raises funds to treat and cure FA through research.
Friday, October 13, 2017
FDA awards six grants for natural history studies in rare diseases
12-10-2017. SILVER SPRING, Md: The U.S. Food and Drug Administration today announced it has awarded six new research grants for natural history studies in rare diseases. The aim of the research is to inform medical product development by better understanding how specific rare diseases progress over time.
Grants being funded by the FDA:
•
•Children's Hospital of Philadelphia, David Lynch, Prospective study in Friedreich's ataxia, approximately $2 million over 5 years
•
Grants being funded by the FDA:
•
•Children's Hospital of Philadelphia, David Lynch, Prospective study in Friedreich's ataxia, approximately $2 million over 5 years
•
Subscribe to:
Posts (Atom)
